MedTrace Logo

Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT00672451 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-12-13

Study results available
· View outcomes & findings →

Summary

Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of this study is to determine the combined effect of rhubarb plus enalapril (an ACEI)in slowing the rate of decline of CKD in people with kidney disease from diabetes.

Conditions

  • Diabetic Kidney Disease

Interventions

DIETARY_SUPPLEMENT

rhubarb extract

titrate rhubarb extract titrated up to 6grams daily by mouth

DIETARY_SUPPLEMENT

placebo

placebo titrated up to 6 pills daily as patient tolerates

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Wake Forest University

    lead OTHER

Principal Investigators

  • John Burkart, MD · Wake Forest University Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-05-31
Completion
2009-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00672451 on ClinicalTrials.gov